{"prompt": "['Tofacitinib', 'A3921284 NON-INTERVENTIONAL STUDY PROTOCOL', 'Amended, 12-December-2018', '-', 'Clinical and demographic information of patients: age, sex, comorbidities, concomitant', 'medications, risk factors', '-', 'Characteristics of the disease: duration of the disease, laboratory test data.', '-', 'Treatment: previous and current treatment', 'Data analysis:', 'The information collected by the Clinical Research Organization (CRO) will be analyzed by Pfizer through a', 'statistical management plan. Initially, the sample will be matched using propensity score calculated from', 'baseline variables. For effectiveness outcomes, a descriptive analysis will be performed for all variables.', 'Second, Functional status (adapted HAQ-DI), Quality of life (EQ-5D), work productivity (WPAI) and', 'Disease activity (RAPID3) will be analyzed with paired t test or Wilcoxon test and will be matched using', 'propensity score to adjust potential confounding variables. For safety outcomes, all the safety data will be', 'summarized through appropriate data tabulations, descriptive statistics, and graphical presentation.', 'First Patient First', '15 April 2017', 'Last Patient Last', '30 August 2019', 'Visit', 'Visit', 'Last Patient First', '28 February 2019', 'Estimated duration', '22 months', 'Visit', 'of recruitment', 'CONFIDENTIAL', 'Page 15 of 64']['Tofacitinib', 'A3921284 NON-INTERVENTIONAL STUDY PROTOCOL', 'Amended, 12-December-2018', '8. AMENDMENTS AND UPDATES', 'Any significant change in the study requires an amendment of the protocol. Any', 'investigator cannot make any changes to the study without the approval of the sponsor and', 'the Ethics Committee. All protocol amendments should be reviewed and approved', 'following the same process as the original protocol.', 'Substantial or', 'Protocol', 'Amendment', 'Date', 'administrative', 'section(s)', 'number', 'Summary of amendment(s)', 'Reason', 'amendment', 'changed', '1', '30-Nov-', 'Administrative', '1-3,6-7,9,', 'Sections of disclosure', 'To adapt the protocol to Latin', '16', '12', 'statement, sponsor and', 'America requirements of', 'Annex 3', 'investigator signature,', 'Ethical Committees', 'flowchart were included', 'There is more experience with', 'Planned dates for milestones', 'EQ-5D-3L version in Latin', 'were updated', 'America', 'Dominican Republic was', 'excluded', 'Sampling process is widely', 'explained', 'Expands on description to', 'analyze the causality and', 'severity of AE', 'Coding of patients', 'description is included', 'EQ-5D-3L version will be', 'used', '2', '03', 'Sustantial', 'Pages 12,', 'The collection process of', 'Authorization by Stanford', 'Dec-18', '14, 21, 27,', 'the HAQ-DI is detailed', 'University to use it in this', '34, 36,', 'since 8 questions of that', 'way.', 'Annex 2', 'questionnaire will be', 'Execute changes in the', 'evaluated in RAPID3.', 'protocol by deviation of', 'It is clarified that an', 'protocol version 2.0', 'adapted HAQ-DI is being', 'used.', '3', '03 Dec', 'Administrative', 'Pages 13,', 'Chile was eliminated as', 'Updating information as', '18', '15, 22, 23,', 'a participating country.', 'the study progresses.', '25', 'The', 'number', 'of', 'participating centers per', 'country was updated.', 'The dates of the study', 'milestones', 'were', 'updated.', 'Page 16 of 64']['Tofacitinib', 'A3921284 NON-INTERVENTIONAL STUDY PROTOCOL', 'Amended, 12-December-2018', '9. MILESTONES', 'Milestone', 'Planned date', 'Final protocol and data collection form', '13 December 2016', 'Start of data collection', '15 April 2017', 'End of data collection', '28 February 2019', 'Final analytic results', '15 November 2019', 'Final study report', '21 December 2019', 'CONFIDENTIAL', 'Page 17 of 64']\n\n###\n\n", "completion": "END"}